This paper describes the production, characterization and in vivo activity of lipid nanocarriers (LN) containing a levodopa prodrug (LD-PD) with therapeutic potential in Parkinson’s disease. LD is the mainstay of the pharmacotherapy of Parkinson’s disease. However, after a good initial response, motor fluctuations, dyskinesia and loss of efficacy, develop over time, partly due to oscillations in plasma and brain levels of the drug. LD-PD was produced with the aim of prolonging the pharmacological activity of LD. To improve solubility, and simultaneously provide a long lasting release and therapeutic efficacy, the prodrug was formulated in tristearin/lecithin LN. The obtained formulation was homogeneous in particle size and remained stable for up to two months from preparation. For the three different tested LD concentrations, namely 1.25, 2.5 and 5.0 mg/ml, the morphological characterization revealed no substantial differences between unloaded and LD-PD loaded LN. The calorimetric test showed an interaction between the lipid phase and the loaded prodrug. In vitro studies using the dialysis method and enzymatic degradation procedure showed that the LD-PD loaded LN provided a controlled prodrug release. Finally, two behavioural tests specific to akinesia (bar test) or akinesia/bradykinesia (drag test) performed in 6-hydroxydopamine hemilesioned mice (a model of Parkinson’s disease) demonstrated that the LD-PD loaded LN attenuated parkinsonian disabilities, showing a slightly reduced maximal efficacy but a longer lasting action (up to 24 hours) than an equal dose of LD. We conclude that LD-PD loaded LN may represent a future LD formulation useful in Parkinson’s disease therapy.

Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity

RAVANI, Laura;ESPOSITO, Elisabetta;CALCAGNO, Mariangela;CONTADO, Catia;LONGO, FRANCESCO;MORARI, Michele
Penultimo
;
CORTESI, Rita
Ultimo
2015

Abstract

This paper describes the production, characterization and in vivo activity of lipid nanocarriers (LN) containing a levodopa prodrug (LD-PD) with therapeutic potential in Parkinson’s disease. LD is the mainstay of the pharmacotherapy of Parkinson’s disease. However, after a good initial response, motor fluctuations, dyskinesia and loss of efficacy, develop over time, partly due to oscillations in plasma and brain levels of the drug. LD-PD was produced with the aim of prolonging the pharmacological activity of LD. To improve solubility, and simultaneously provide a long lasting release and therapeutic efficacy, the prodrug was formulated in tristearin/lecithin LN. The obtained formulation was homogeneous in particle size and remained stable for up to two months from preparation. For the three different tested LD concentrations, namely 1.25, 2.5 and 5.0 mg/ml, the morphological characterization revealed no substantial differences between unloaded and LD-PD loaded LN. The calorimetric test showed an interaction between the lipid phase and the loaded prodrug. In vitro studies using the dialysis method and enzymatic degradation procedure showed that the LD-PD loaded LN provided a controlled prodrug release. Finally, two behavioural tests specific to akinesia (bar test) or akinesia/bradykinesia (drag test) performed in 6-hydroxydopamine hemilesioned mice (a model of Parkinson’s disease) demonstrated that the LD-PD loaded LN attenuated parkinsonian disabilities, showing a slightly reduced maximal efficacy but a longer lasting action (up to 24 hours) than an equal dose of LD. We conclude that LD-PD loaded LN may represent a future LD formulation useful in Parkinson’s disease therapy.
2015
Ravani, Laura; M. G., Sarpietro; Esposito, Elisabetta; A., Di Stefano; P., Sozio; Calcagno, Mariangela; M., Drechsler; Contado, Catia; Longo, Francesc...espandi
File in questo prodotto:
File Dimensione Formato  
lipid nanocarriers_MSEC2015.pdf

solo gestori archivio

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 709.2 kB
Formato Adobe PDF
709.2 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
11392_2275622_postprint_Cortesi_Rita.pdf

accesso aperto

Descrizione: post print
Tipologia: Post-print
Licenza: Creative commons
Dimensione 1.42 MB
Formato Adobe PDF
1.42 MB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2275622
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact